Who are mometasone furoate plus azelastine HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone furoate and fexofenadine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mometasone-furoate-plus-azelastine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

mometasone furoate plus azelastine HCl — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mometasone furoate plus azelastine HCl (mometasone furoate plus azelastine HCl) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid and antihistamine combination. Area: Ophthalmology.

phase 3 Corticosteroid and antihistamine combination Histamine receptors (H1) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

mometasone furoate plus azelastine HCl (mometasone furoate plus azelastine HCl) — Hanlim Pharm. Co., Ltd.. Mometasone furoate is a corticosteroid that reduces inflammation, while azelastine HCl is an antihistamine that blocks histamine receptors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mometasone furoate plus azelastine HCl TARGET	mometasone furoate plus azelastine HCl	Hanlim Pharm. Co., Ltd.	phase 3	Corticosteroid and antihistamine combination	Histamine receptors (H1)
Fluticasone furoate and fexofenadine	Fluticasone furoate and fexofenadine	GlaxoSmithKline	marketed	Intranasal corticosteroid and antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid and antihistamine combination class)

Hanlim Pharm. Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mometasone furoate plus azelastine HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/mometasone-furoate-plus-azelastine-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab